A model-based economic evaluation was performed to estimate costs as well as outcomes of vaccination with PCV10 and PCV13 compared to ‘no vaccination’. This study considered two commonly recommended regimens: two-dose primary series at 2 and 4 months of age plus a booster dose at age 13 months (2+1) and three-dose primary series at 2, 4 and 6 m

Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: Protection at what price in the Thai context? Wantanee Kulpenga, b, , , , Pattara Leelahavaronga, , Waranya Rattanavipaponga, , Vorasith Sornsrivichaib, , Henry C. Baggettc, , Aronrag Meeyaia, d, , , Warunee Punpaniche, ,

Beyond vaccine safety, efficacy and procurement lie licensing and delivery — nations must get ready. There are currently more than 40 candidate vaccines for COVID-19 in clinical evaluation, and more than 150 in preclinical development. Creating a safe and effective vaccine is akin to striking bas

Manuel Alexander Haasis1*, Joyce Anne Ceria1, Wantanee Kulpeng2, Yot Teerawattananon2, Marissa Alejandria3 1 National Center for Pharmaceutical Access and Management (NCPAM), Department of Health, Manila, Philippines, 2 Health Intervention and Technology Assessment Program (HITAP), Department of

The introduction of Coronavirus disease 2019 (COVID-19) vaccines urged all Thais to seek prevention of serious illness and death from COVID-19. However, immunocompromised individuals might not be able to achieve an efficient immune response from these vaccines. This study aimed to evaluate the cost-

Economic Evaluation of Policy Options for Prevention and Control of Cervical Cancer in Thailand Naiyana Praditsitthikorn,1,2 Yot Teerawattananon,1,3 Sripen Tantivess,1,3 Supon Limwattananon,3 Arthorn Riewpaiboon,2 Saibua Chichareon,4 Nantakan Ieumwananonthachai5 and Viroj Tangcharoensathien3

Abstract Background: Diarrhoea remains one of the top ten causes of under-five child morbidity in Bhutan, and rotavirus is a significant cause of child diarrhoeal hospitalisations. This study sought to determine the health outcomes, cost-effectiveness, and budget and human resource implications o

Bhutan is a rapidly growing economy that is transitioning from international donor support. As such, the country is looking for ways to ensure that they continue to provide the adequate services and support for their population in a rational and sustainable manner. Bhutan has begun using health tech

As we approach the end of an unprecedented year, the approval of select COVID-19 vaccines by stringent regulatory authorities and programmatic roll-out has been cause for optimism. However, it is imperative to assure equitable access to those in need in all regions of the world as a core component o

Veronika J Wirtz*, Hans V Hogerzeil*, Andrew L Gray*, Maryam Bigdeli, Cornelis P de Joncheere, Margaret A Ewen, Martha Gyansa-Lutterodt, Sun Jing, Vera L Luiza, Regina M Mbindyo, Helene Möller, Corrina Moucheraud, Bernard Pécoul, Lembit Rägo, Arash Rashidian, Dennis Ross-Degnan, Peter N Stephens,